Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review

Publisher： Bentham Science Publishers

E-ISSN： 1874-4745|4|2|87-94

ISSN： 1874-4737

Source： Current Drug Abuse Reviews, Vol.4, Iss.2, 2011-06, pp. : 87-94

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor

By Sommer Frank  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 1, Iss. 2, 2005-08 ,pp. : 295-301

Informa Healthcare

Access to resources Recommend Favorite

FR226807: a potent and selective phosphodiesterase type 5 inhibitor

By Hosogai N.   Hamada K.   Tomita M.   Nagashima A.   Takahashi T.   Sekizawa T.   Mizutani T.   Urano Y.   Kuroda A.   Sawada K.   Ozaki T.   Seki J.   Goto T.  

European Journal of Pharmacology, Vol. 428, Iss. 2, 2001-10 ,pp. : 295-302

Elsevier

Access to resources Recommend Favorite

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

By Kendirci Muammer   Bivalacqua Trinity J   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 923-932

Informa Healthcare

Access to resources Recommend Favorite

Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859

By Qiu Y.   Bhattacharjee S.   Kraft P.   John T.M.   Craig E.   Haynes-Johnson D.   Guan J.   Jiang W.   Macielag M.   Sui Z.   Clancy J.   Lundeen S.  

European Journal of Pharmacology, Vol. 472, Iss. 1, 2003-07 ,pp. : 73-80

Elsevier

Access to resources Recommend Favorite

Vision Disorders and Phosphodiesterase Type 5 Inhibitors: A Review of the Evidence to Date

By Laties Alan M.  

Drug Safety, Vol. 32, Iss. 1, 2009-01 ,pp. : 1-18

Adis International

Access to resources Recommend Favorite